Search Result

Results for "

airway fibrosis

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CFTR (1) 5-HT Receptor (1) Apoptosis (3) Bacterial (2) c-Fms (1) Calcium Channel (3) COX (3) DNA/RNA Synthesis (1) Drug Intermediate (1) Endonuclease (1) IFNAR (2) Interleukin Related (4) Isotope-Labeled Compounds (1) MMP (2) NF-κB (3) Reference Standards (1) Sodium Channel (1) TGF-β Receptor (5) TNF Receptor (3) TRP Channel (1)
By Research Areas:	Cancer (1) Cardiovascular Disease (1) Infection (2) Inflammation/Immunology (13) Metabolic Disease (1) Neurological Disease (3)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Isotope-Labeled Compounds

Targets Recommended: CFTR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16657

TAPI-1 10+ Cited Publications	MMP NF-κB Apoptosis TNF Receptor	Inflammation/Immunology Cancer
TAPI-1 is a broad-spectrum MMP inhibitor and NF-κB p65 inhibitor that targets ADAM17/TACE, ADAM10 and other proteins. TAPI-1 reduces the proteolytic cleavage of membrane-bound TNF-α, decreases TNF-α levels, inhibits NF-κB pathway activation, and downregulates profibrotic markers. TAPI-1 reduces the proportion of proinflammatory immune cells, alleviates cardiac and airway fibrosis, and improves cardiac function after myocardial infarction. Meanwhile, TAPI-1 inhibits the viability, migration and invasion of esophageal squamous cell carcinoma cells, enhances the chemosensitivity of Cisplatin (HY-17394), induces apoptosis, and shows low toxicity to normal esophageal epithelial cells. TAPI-1 can be widely used in studies related to myocardial infarction-induced heart failure, severe traumatic tracheal stenosis, esophageal squamous cell carcinoma and other conditions .

HY-156963

Aderamastat FP-025	MMP	Inflammation/Immunology
Aderamastat (FP-025) is an orally active, selective MMP-12 inhibitor. Aderamastat provides protection against house dust mite (HDM)-sensitized allergic asthma. Aderamastat can be used in the research of respiratory diseases, including chronic inflammatory airway diseases and pulmonary fibrosis .

HY-108858

Dornase alfa 1 Publications Verification rhDNase	DNA/RNA Synthesis Endonuclease	Inflammation/Immunology
Dornase alfa (rhDNase) is a recombinant human deoxyribonuclease I (rhDNase) that can specifically degrade extracellular DNA. Dornase alfa catalyzes the cleavage of DNA released by neutrophils in respiratory mucus, reduces sputum viscosity, thereby improving mucus clearance efficiency, reducing airway obstruction and alleviating inflammatory responses. Dornase alfa can be used to improve lung function (such as FEV_1) in cystic fibrosis (CF), reduce the risk of acute pulmonary exacerbations, and has good in vivo tolerability. Dornase alfa acts locally on the respiratory tract through aerosol inhalation, specifically improving the high viscosity of mucus caused by DNA accumulation and related respiratory symptoms .

HY-P990094

Trabikibart CSL311	c-Fms	Inflammation/Immunology
Trabikibart (CSL311) is a specific inhibitor targeting the βc receptor (CSF2RB) that inhibits signal transduction mediated by GM-CSF, IL-5, and IL-3. Trabikibart exhibits significant anti-inflammatory and anti-edema effects, reduces myeloid cell infiltration, and inhibits inflammatory cell survival. Trabikibart also possesses antiviral immune functions, which alleviate pulmonary inflammation, reverse airway dysfunction and fibrosis, and thereby restore impaired pulmonary function. Trabikibart can be used in research on related diseases such as acute respiratory distress syndrome, viral pneumonia, asthma, and chronic rhinosinusitis with nasal polyps .

HY-108464A

Phenamil methanesulfonate	Sodium Channel TRP Channel	Metabolic Disease Inflammation/Immunology
Phenamil methanesulfonate, an analog of Amiloride (HY-B0285), is a more potent and less reversible epithelial sodium channel (ENaC) blocker with an IC₅₀ of 400 nM . Phenamil methanesulfonate is also a competive inhibitor of TRPP3 and inhibits TRPP3-mediated Ca ²⁺ transport with an IC₅₀ of 140 nM in a Ca ²⁺ uptake assay . Phenamil methanesulfonate is an intriguing small molecule to promote bone repair by strongly activating BMP signaling pathway . Phenamil methanesulfonate is used for the research of cystic fibrosis lung disease .

HY-P99193

Enokizumab MEDI-528	Interleukin Related	Inflammation/Immunology
Enokizumab (MEDI-528) is a monoclonal antibody targeting to interleukin (IL)-9. IL-9 regulates the development of airway inflammation, mucus production, airway hyperresponsiveness, and airway fibrosis largely by increasing mast cell numbers and activity in the airways .

HY-121235

Clonixin SCH-10304	COX Calcium Channel TGF-β Receptor	Neurological Disease Inflammation/Immunology
Clonixin (SCH-10304) is an orally active non-steroidal anti-inflammatory agent (NSAID) that inhibits COX synthesis. Clonixin acts as a voltage-gated L-type calcium channel blocker, exerts vasodilatory effects by antagonizing Ca ²⁺ in vascular smooth muscle. Clonixin inhibits TGF-β, reduces lung coefficient, immune cell infiltration level, oxidative stress response, airway resistance, hydroxyproline content and collagen deposition. Clonixin can be used in research related to inflammation such as idiopathic pulmonary fibrosis and moderate to severe pain .

HY-P11085

WLBU2	Bacterial	Infection
WLBU2 is a engineered cationic antimicrobial peptide (eCAP) that overcomes the environmental sensitivity of natural antimicrobial peptides (AMPs). WLBU2 exhibits rapid bactericidal effect, with the MIC values of ≤ 10 μM against both Gram-negative and Gram-positive bacteria including MRSA, vancomycin-resistant enterococci, K. pneumoniae, E.aerogenes, E. cloacae, Escherichia coli, et, al. WLBU2 prevents P. aeruginosa biofilm growth and retains its activity in an environment rich in mucus, low pH and high salt concentrations without negative effects on human airway epithelial cells. WLBU2 can be used for the studies of cystic fibrosis (CF) and Pseudomonas aeruginosa infections .

HY-16363

Omtriptolide PG 490-88	Apoptosis TGF-β Receptor NF-κB Interleukin Related IFNAR TNF Receptor	Inflammation/Immunology
Omtriptolide (PG490-88) is a derivative proagent of triptolide purified from the Chinese herb.

HY-119229

VRT-325	CFTR	Inflammation/Immunology
VRT-325 is a CFTR modulator. VRT-325 inhibits disulfide cross-linking between cysteines in transmembrane segments 6 and 7 of CFTR and P-gp. VRT-325 promotes maturation of CFTR and P-gp processing mutants, rescues ΔF508-CFTR folding at the endoplasmic reticulum. VRT-325 binds ΔF508-CFTR nucleotide-binding domain 1, and increases mature ΔF508-CFTR cell surface expression and chloride conductance. VRT-325 can be used for the research of cystic fibrosis ^[1] ^[3].

HY-161815

Anti-inflammatory agent 89	Drug Intermediate Interleukin Related	Inflammation/Immunology
Anti-inflammatory agent 89 is a multi-target glucocorticoid-isothiocyanate hybrid with anti-inflammatory activity. Anti-inflammatory agent 89 releases hydrogen sulfide via its isothiocyanate group, inhibits antigen-induced mast cell degranulation, alleviates pulmonary inflammation, and suppresses bronchial hyperresponsiveness and airway fibrosis. Anti-inflammatory agent 89 can be used in asthma research .

HY-170387

MRS8209	5-HT Receptor	Cardiovascular Disease
MRS8209 is the antagonist for serotonin receptor with a K_i of 4.27 nM for 5-HT2BR. MRS8209 exhibits protective effect on pressure at airway opening (PAO), and can be used in research of pulmonary fibrosis .

HY-121235R

Clonixin (Standard) SCH-10304 (Standard)	Reference Standards COX Calcium Channel TGF-β Receptor	Neurological Disease Inflammation/Immunology
Clonixin (SCH-10304) (Standard) is the analytical standard of Clonixin. This product is intended for research and analytical applications. Clonixin is an orally active non-steroidal anti-inflammatory agent (NSAID) that inhibits COX synthesis. Clonixin acts as a voltage-gated L-type calcium channel blocker, exerts vasodilatory effects by antagonizing Ca ²⁺ in vascular smooth muscle. Clonixin inhibits TGF-β, reduces lung coefficient, immune cell infiltration level, oxidative stress response, airway resistance, hydroxyproline content and collagen deposition. Clonixin can be used in research related to inflammation such as idiopathic pulmonary fibrosis and moderate to severe pain .

HY-16362

Omtriptolide sodium PG 490-88Na	Apoptosis TGF-β Receptor NF-κB Interleukin Related IFNAR TNF Receptor	Inflammation/Immunology
Omtriptolide sodium (PG490-88Na) is a derivative of Triptolide (HY-32735). Omtriptolide sodium exhibits significant immunosuppressive, anti-fibrotic and anti-inflammatory properties. The mechanism of action of Omtriptolide sodium is diverse, including inhibiting T cell activation and proliferation, inducing T cell apoptosis (apoptosis), blocking fibroblast maturation/proliferation, inhibiting TGF-β mRNA expression, and suppressing pro-inflammatory cytokines (such as IL-2, IFN-γ, TNF-α) by blocking transcription factors such as NF-κB. Omtriptolide sodium can be used for research on obstructive airway diseases, pulmonary fibrosis and graft-versus-host disease .

HY-P11085A

WLBU2 acetate	Bacterial	Infection
WLBU2 acetate is a engineered cationic antimicrobial peptide (eCAP) that overcomes the environmental sensitivity of natural antimicrobial peptides (AMPs). WLBU2 acetate exhibits rapid bactericidal effect, with the MIC values of ≤ 10 μM against both Gram-negative and Gram-positive bacteria including MRSA, vancomycin-resistant enterococci, K. pneumoniae, E.aerogenes, E. cloacae, Escherichia coli, et, al. WLBU2 acetate prevents P. aeruginosa biofilm growth and retains its activity in an environment rich in mucus, low pH and high salt concentrations without negative effects on human airway epithelial cells. WLBU2 acetate can be used for the studies of cystic fibrosis (CF) and Pseudomonas aeruginosa infections .

HY-121235S1

Clonixin-13C,d3 SCH-10304-¹³C,d₃	Isotope-Labeled Compounds COX Calcium Channel TGF-β Receptor	Neurological Disease Inflammation/Immunology
Clonixin- ¹³C,d₃ (SCH-10304- ¹³C,d₃) is the deuterium and ¹³C-labeled Clonixin (HY-121235). Clonixin is an orally active non-steroidal anti-inflammatory agent (NSAID) that inhibits COX synthesis. Clonixin acts as a voltage-gated L-type calcium channel blocker, exerts vasodilatory effects by antagonizing Ca ²⁺ in vascular smooth muscle. Clonixin inhibits TGF-β, reduces lung coefficient, immune cell infiltration level, oxidative stress response, airway resistance, hydroxyproline content and collagen deposition. Clonixin can be used in research related to inflammation such as idiopathic pulmonary fibrosis and moderate to severe pain.

Cat. No.	Product Name	Target	Research Area

HY-P11085

WLBU2	Bacterial	Infection
WLBU2 is a engineered cationic antimicrobial peptide (eCAP) that overcomes the environmental sensitivity of natural antimicrobial peptides (AMPs). WLBU2 exhibits rapid bactericidal effect, with the MIC values of ≤ 10 μM against both Gram-negative and Gram-positive bacteria including MRSA, vancomycin-resistant enterococci, K. pneumoniae, E.aerogenes, E. cloacae, Escherichia coli, et, al. WLBU2 prevents P. aeruginosa biofilm growth and retains its activity in an environment rich in mucus, low pH and high salt concentrations without negative effects on human airway epithelial cells. WLBU2 can be used for the studies of cystic fibrosis (CF) and Pseudomonas aeruginosa infections .

HY-P11085A

WLBU2 acetate	Bacterial	Infection
WLBU2 acetate is a engineered cationic antimicrobial peptide (eCAP) that overcomes the environmental sensitivity of natural antimicrobial peptides (AMPs). WLBU2 acetate exhibits rapid bactericidal effect, with the MIC values of ≤ 10 μM against both Gram-negative and Gram-positive bacteria including MRSA, vancomycin-resistant enterococci, K. pneumoniae, E.aerogenes, E. cloacae, Escherichia coli, et, al. WLBU2 acetate prevents P. aeruginosa biofilm growth and retains its activity in an environment rich in mucus, low pH and high salt concentrations without negative effects on human airway epithelial cells. WLBU2 acetate can be used for the studies of cystic fibrosis (CF) and Pseudomonas aeruginosa infections .

Cat. No.	Product Name	Target	Research Area	Image

HY-P990094

Trabikibart CSL311	c-Fms	Inflammation/Immunology
Trabikibart (CSL311) is a specific inhibitor targeting the βc receptor (CSF2RB) that inhibits signal transduction mediated by GM-CSF, IL-5, and IL-3. Trabikibart exhibits significant anti-inflammatory and anti-edema effects, reduces myeloid cell infiltration, and inhibits inflammatory cell survival. Trabikibart also possesses antiviral immune functions, which alleviate pulmonary inflammation, reverse airway dysfunction and fibrosis, and thereby restore impaired pulmonary function. Trabikibart can be used in research on related diseases such as acute respiratory distress syndrome, viral pneumonia, asthma, and chronic rhinosinusitis with nasal polyps .

HY-P99193

Enokizumab MEDI-528	Interleukin Related	Inflammation/Immunology
Enokizumab (MEDI-528) is a monoclonal antibody targeting to interleukin (IL)-9. IL-9 regulates the development of airway inflammation, mucus production, airway hyperresponsiveness, and airway fibrosis largely by increasing mast cell numbers and activity in the airways .

Cat. No.	Product Name	Chemical Structure

HY-121235S1

Clonixin-13C,d3
Clonixin- ¹³C,d₃ (SCH-10304- ¹³C,d₃) is the deuterium and ¹³C-labeled Clonixin (HY-121235). Clonixin is an orally active non-steroidal anti-inflammatory agent (NSAID) that inhibits COX synthesis. Clonixin acts as a voltage-gated L-type calcium channel blocker, exerts vasodilatory effects by antagonizing Ca ²⁺ in vascular smooth muscle. Clonixin inhibits TGF-β, reduces lung coefficient, immune cell infiltration level, oxidative stress response, airway resistance, hydroxyproline content and collagen deposition. Clonixin can be used in research related to inflammation such as idiopathic pulmonary fibrosis and moderate to severe pain.

Clonixin-13C,d3

Clonixin- ¹³C,d₃ (SCH-10304- ¹³C,d₃) is the deuterium and ¹³C-labeled Clonixin (HY-121235). Clonixin is an orally active non-steroidal anti-inflammatory agent (NSAID) that inhibits COX synthesis. Clonixin acts as a voltage-gated L-type calcium channel blocker, exerts vasodilatory effects by antagonizing Ca ²⁺ in vascular smooth muscle. Clonixin inhibits TGF-β, reduces lung coefficient, immune cell infiltration level, oxidative stress response, airway resistance, hydroxyproline content and collagen deposition. Clonixin can be used in research related to inflammation such as idiopathic pulmonary fibrosis and moderate to severe pain.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.